RELAPSED/REFRACTORY MULTIPLE MYELOMA

This early-stage study tests whether combining two types of immune-boosting drugs (bispecific antibodies and a checkpoint inhibitor) is safe for people with multiple myeloma that has come back or stopped responding to treatment. About 74 participants will receive either talquetam…

This study was designed to test a new type of cell therapy (BCMA-GPRC5D CAR-T) for people with relapsed/refractory multiple myeloma, a blood cancer that had not responded to at least three prior treatments. The goal was to check the treatment's safety and early signs of effective…

This early-phase trial aimed to test a new immune cell therapy called BCMA/GPRC5D CAR-T in people with relapsed or refractory multiple myeloma. The study was designed to check safety and dosing, but it was withdrawn before any patients were enrolled. No results are available.

This study tests a drug combination (isatuximab, carfilzomib, and dexamethasone) given under the skin to adults whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to see how well the cancer responds and to compare two ways of giving th…

This study tests whether adding a drug called cevostamab after standard CAR T cell therapy can help people with relapsed or refractory multiple myeloma achieve a deeper remission. About 30 adults who have already received CAR T cells will get cevostamab infusions every 3 weeks fo…

This early-stage study tests a new drug called etentamig combined with standard treatments for people with multiple myeloma that has come back or stopped responding to therapy. About 320 adults will take part to find the safest dose and check for side effects. The goal is to cont…

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…